Literature DB >> 29530844

Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.

Mahdi Abastabar1, Abdullah M S Al-Hatmi2,3,4, Mohammad Vafaei Moghaddam5, G Sybren de Hoog2,3, Iman Haghani1, Seyed Reza Aghili1, Tahereh Shokohi1, Mohammad Taghi Hedayati1, Roshanak Daie Ghazvini6, Reza Kachuei7, Ali Rezaei-Matehkolaei8, Koichi Makimura9,10, Jacques F Meis3,11, Hamid Badali12,13.   

Abstract

A collection of clinical (n = 47) and environmental (n = 79) Fusarium isolates were tested against 10 antifungal drugs, including 2 novel imidazoles. Luliconazole and lanoconazole demonstrated very low geometric mean MIC values of 0.005 and 0.013 μg/ml, respectively, compared with 0.51 μg/ml for micafungin, 0.85 μg/ml for efinaconazole, 1.12 μg/ml for natamycin, 1.18 μg/ml for anidulafungin, 1.31 μg/ml for voriconazole, 1.35 μg/ml for caspofungin, 1.9 μg/ml for amphotericin B, and 4.08 μg/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due to Fusarium species.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Fusarium species; intrinsic resistance; lanoconazole; luliconazole

Mesh：

Substances：

Year:  2018        PMID： 29530844      PMCID： PMC5923147          DOI： 10.1128/AAC.00009-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin.

Authors:  John Apostolidis; Maria Bouzani; Evangelia Platsouka; Helen Belasiotou; Maria Stamouli; Nikolaos Harhalakis; Eleni I Boutati; Olga Paniara; Emmanuel Nikiforakis
Journal:  Clin Infect Dis       Date:  2003-05-15       Impact factor: 9.079

2.  In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives.

Authors:  Gholam Reza Shokoohi; Hamid Badali; Hossein Mirhendi; Saham Ansari; Ali Rezaei-Matehkolaei; Bahram Ahmadi; Afsane Vaezi; Mohamed Mahdi Alshahni; Koichi Makimura
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex.

Authors:  Abdullah M S Al-Hatmi; Anne D van Diepeningen; Ilse Curfs-Breuker; G Sybren de Hoog; Jacques F Meis
Journal:  J Antimicrob Chemother       Date:  2014-12-23       Impact factor: 5.790

4.  In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.

Authors:  Gloria M González
Journal:  Med Mycol       Date:  2008-12-18       Impact factor: 4.076

5.  Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium.

Authors:  Tatiana B Spader; Tarcieli P Venturini; Luana Rossato; Laura B Denardi; Patricia B Cavalheiro; Sonia A Botton; Janio M Santurio; Sydney Hartz Alves
Journal:  Rev Iberoam Micol       Date:  2013-02-09       Impact factor: 1.044

6.  International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method.

Authors:  A Espinel-Ingroff; A L Colombo; S Cordoba; P J Dufresne; J Fuller; M Ghannoum; G M Gonzalez; J Guarro; S E Kidd; J F Meis; T M S C Melhem; T Pelaez; M A Pfaller; M W Szeszs; J P Takahaschi; A M Tortorano; N P Wiederhold; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 7.  Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment.

Authors:  J Guarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-11       Impact factor: 3.267

8.  In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis.

Authors:  Abdullah M S Al-Hatmi; Joseph Meletiadis; Ilse Curfs-Breuker; Alexandro Bonifaz; Jacques F Meis; G Sybren De Hoog
Journal:  J Antimicrob Chemother       Date:  2015-12-24       Impact factor: 5.790

9.  In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates.

Authors:  Nesa Baghi; Tahereh Shokohi; Hamid Badali; Koichi Makimura; Ali Rezaei-Matehkolaei; Maryam Abdollahi; Mojtaba Didehdar; Iman Haghani; Mahdi Abastabar
Journal:  Med Mycol       Date:  2016-04-26       Impact factor: 4.076

10.  Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience.

Authors:  Jessica M Stempel; Sarah P Hammond; Deanna A Sutton; Linda M Weiser; Francisco M Marty
Journal:  Open Forum Infect Dis       Date:  2015-07-04       Impact factor: 3.835
View more
  8 in total

1.  Disseminated fusariosis with ecthyma gangrenosum-like lesions in a refractory acute myeloid leukemia patient.

Authors:  Masoud Mardani; Rozita Khodashahi; Ensieh Lotfali; Sara Abolghasemi; Mojhde Hakemi-Vala
Journal:  Curr Med Mycol       Date:  2019-03

2.  Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates.

Authors:  Zahra Taheri Rizi; Mahdi Abastabar; Hamed Fakhim; Macit Ilkit; Fatemeh Ahangarkani; Javad Javidnia; Iman Haghani; Jacques F Meis; Hamid Badali
Journal:  Mycopathologia       Date:  2020-02-28       Impact factor: 2.574

3.  Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis.

Authors:  Mahdi Abastabar; Iman Haghani; Tahereh Shokohi; Mohammad Taghi Hedayati; Seyed Reza Aghili; Ali Jedi; Sulmaz Dadashi; Shafigheh Shabanzadeh; Tahereh Hosseini; Narges Aslani; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

4.  Molecular identification of Fusarium species complex isolated from clinical samples and its antifungal susceptibility patterns.

Authors:  Yashik Bansal; Nidhi Singla; Neelam Kaistha; Sunandan Sood; Jagdish Chander
Journal:  Curr Med Mycol       Date:  2019

5.  High prevalence of itraconazole resistance among Candida parapsilosis isolated from Iran.

Authors:  Fozieh Hassanmoghadam; Tahereh Shokohi; Mohammad Taghi Hedayati; Narges Aslani; Iman Haghani; Mojtaba Nabili; Ensieh Lotfali; Amirhossein Davari; Maryam Moazeni
Journal:  Curr Med Mycol       Date:  2019-09

6.  Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.

Authors:  Bertrand Nyuykonge; Wilson Lim; Lukas van Amelsvoort; Alexandro Bonifaz; Ahmed Fahal; Hamid Badali; Mahdi Abastabar; Annelies Verbon; Wendy van de Sande
Journal:  Mycoses       Date:  2022-05-06       Impact factor: 4.931

7.  In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins Resistant Fusarium Strains.

Authors:  Mohsen Nosratabadi; Javad Akhtari; Leila Faeli; Iman Haghani; Seyed Reza Aghili; Tahereh Shokohi; Mohammad Taghi Hedayati; Hossein Zarrinfar; Rasoul Mohammadi; Mohammad Javad Najafzadeh; Sadegh Khodavaisy; Ahmed Al-Harrasi; Mohammad Javan-Nikkhah; Reza Kachuei; Maryam Salimi; Mahsa Fattahi; Hamid Badali; Abdullah M S Al Hatmi; Mahdi Abastabar
Journal:  J Fungi (Basel)       Date:  2022-07-04

8.  A 23 bp cyp51A Promoter Deletion Associated With Voriconazole Resistance in Clinical and Environmental Isolates of Neocosmospora keratoplastica.

Authors:  Jasper Elvin James; Erwin Lamping; Jacinta Santhanam; Trudy Jane Milne; Mohd Fuat Abd Razak; Latiffah Zakaria; Richard David Cannon
Journal:  Front Microbiol       Date:  2020-03-31       Impact factor: 5.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.